company background image
ILA

Island Pharmaceuticals ASX:ILA Stock Report

Last Price

AU$0.19

Market Cap

AU$15.4m

7D

-7.3%

1Y

-29.6%

Updated

06 Dec, 2022

Data

Company Financials
ILA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ILA Stock Overview

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections.

Island Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Island Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.19
52 Week HighAU$0.29
52 Week LowAU$0.12
Beta0
1 Month Change5.56%
3 Month Change15.15%
1 Year Change-29.63%
3 Year Changen/a
5 Year Changen/a
Change since IPO-63.81%

Recent News & Updates

Recent updates

Shareholder Returns

ILAAU PharmaceuticalsAU Market
7D-7.3%-6.1%1.0%
1Y-29.6%-26.2%-2.2%

Return vs Industry: ILA underperformed the Australian Pharmaceuticals industry which returned -26.2% over the past year.

Return vs Market: ILA underperformed the Australian Market which returned -2.2% over the past year.

Price Volatility

Is ILA's price volatile compared to industry and market?
ILA volatility
ILA Average Weekly Movement20.5%
Pharmaceuticals Industry Average Movement10.2%
Market Average Movement8.9%
10% most volatile stocks in AU Market15.9%
10% least volatile stocks in AU Market4.1%

Stable Share Price: ILA is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: ILA's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2017n/aDavid Fosterhttps://www.islandpharmaceuticals.com

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development.

Island Pharmaceuticals Limited Fundamentals Summary

How do Island Pharmaceuticals's earnings and revenue compare to its market cap?
ILA fundamental statistics
Market CapAU$15.44m
Earnings (TTM)-AU$2.61m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ILA income statement (TTM)
RevenueAU$0
Cost of RevenueAU$0
Gross ProfitAU$0
Other ExpensesAU$2.61m
Earnings-AU$2.61m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.032
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did ILA perform over the long term?

See historical performance and comparison